Tarsus Pharmaceuticals, Inc. (TARS) Total Assets by Year
Tarsus Pharmaceuticals, Inc. closed fiscal year 2025 with $562.2M in total assets, $218.7M in total liabilities and $343.4M in shareholder equity. This represents an increase of 49.1% from the prior fiscal year. The table below carries 8 fiscal years, from 2018 to 2025, and the quarters Tarsus Pharmaceuticals, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
TARS Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $562.2M+49.1% | $377.0M+42.0% | $265.5M+16.5% | $227.9M+27.4% | $178.9M+4.0% | $172.0M+194.9% | $58.3M | N/A |
| Total Liabilities | $218.7M+43.5% | $152.5M+122.6% | $68.5M+95.9% | $35.0M+187.1% | $12.2M+103.2% | $6.0M-90.7% | $64.3M | N/A |
| Total Equity | $343.4M+53.0% | $224.5M+14.0% | $197.0M+2.1% | $192.9M+15.7% | $166.7M+0.5% | $166.0M+2864.0% | -$6.0M-343.5% | -$1.4M |
TARS Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $611.1M+23.5% | $581.1M+16.1% | $562.2M+49.1% | $534.6M+42.1% | $495.0M+31.4% | $500.8M+43.4% | $377.0M+42.0% | $376.3M+40.2% | $376.8M+99.5% | $349.3M+65.4% | $265.5M+16.5% | $268.3M+13.5% |
| Total Liabilities | $264.4M+62.8% | $232.2M+46.7% | $218.7M+43.5% | $199.5M+43.7% | $162.4M+30.3% | $158.3M+113.7% | $152.5M+122.6% | $138.8M+153.9% | $124.6M+202.4% | $74.1M+95.9% | $68.5M+95.9% | $54.7M+61.6% |
| Total Equity | $346.7M+4.2% | $349.0M+1.9% | $343.4M+53.0% | $335.1M+41.1% | $332.6M+31.9% | $342.5M+24.4% | $224.5M+14.0% | $237.5M+11.1% | $252.2M+70.7% | $275.2M+58.7% | $197.0M+2.1% | $213.7M+5.4% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Tarsus Pharmaceuticals, Inc. financials
Frequently Asked Questions
What was Tarsus Pharmaceuticals, Inc.'s total assets in fiscal year 2025?
Tarsus Pharmaceuticals, Inc. closed fiscal year 2025 with $562.2M in total assets, $218.7M in total liabilities and $343.4M in shareholder equity.
How fast is Tarsus Pharmaceuticals, Inc.'s total assets growing?
Tarsus Pharmaceuticals, Inc. (TARS) total assets rose by 49.1% year over year, from $377.0M to $562.2M in fiscal year 2025.
What was Tarsus Pharmaceuticals, Inc.'s total assets in the most recent quarter?
Tarsus Pharmaceuticals, Inc. (TARS) reported $611.1M in total assets in Q2 2026. This represents an increase of 23.5% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Tarsus Pharmaceuticals, Inc. (TARS) reported on that line in every period on record.